Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 38.81 USD 2.51% Market Closed
Market Cap: 3.2B USD
Have any thoughts about
Verona Pharma PLC?
Write Note

Operating Margin
Verona Pharma PLC

-2 762.8%
Current
-4 897%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 762.8%
=
Operating Profit
-155.4m
/
Revenue
5.6m

Operating Margin Across Competitors

Country UK
Market Cap 3.2B USD
Operating Margin
-2 763%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Country IE
Market Cap 146B USD
Operating Margin
11%
No Stocks Found

Verona Pharma PLC
Glance View

Market Cap
3.2B USD
Industry
Pharmaceuticals

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm's product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the enzyme's phosphodiesterase 3 and 4 (PDE3 and PDE4), which is designed to act as both a bronchodilator and an anti-inflammatory agent. The firm is developing ensifentrine in three formulations for mostly used inhalation devices, such as nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The company is evaluating nebulized ensifentrine in a Phase III clinical program ENHANCE (Ensifentrine as an inhaled nebulized chronic obstructive pulmonary disease (COPD) therapy) for COPD maintenance treatment. Verona Pharma, Inc. is its wholly owned subsidiary.

VRNA Intrinsic Value
15.98 USD
Overvaluation 59%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 762.8%
=
Operating Profit
-155.4m
/
Revenue
5.6m
What is the Operating Margin of Verona Pharma PLC?

Based on Verona Pharma PLC's most recent financial statements, the company has Operating Margin of -2 762.8%.